drugset / Trial / NCT00580619

Autonomic Nervous System and Chronic Fatigue Syndrome

NCT00580619

Phase 1 Completed 170 enrolled Vanderbilt University
Non-randomizedParallel-groupOpen-label

Summary

The investigators propose to test the hypothesis that the sympathetic nervous system contributes to the cardiovascular and inflammatory abnormalities present in the chronic fatigue syndrome (CFS) and, in particular in the subset of patients characterized by postural tachycardia syndrome (POTS). CFS and POTS are seen mostly in otherwise normal young women, and are the cause of significant disability. A substantial proportion of patients referred for evaluation of POTS met diagnostic criteria for CFS and, conversely, a subset of patients referred for treatment for CFS have POTS. The investigators hypothesize that sympathetic activation underlies the pathophysiology of patients in whom CFS and POTS overlap (CFS-P).

Timeline

Start
2007-04
Primary completion
2017-01
Completion
2017-01

Drugs

EvaluationDrugModalityDoseRoute
Subject L-NMMA Unknown 500 mg/kg Intravenous
Comparator Methyldopa Unknown Oral
Subject Trimethaphan Small molecule 4 mg Intravenous
Subject Trimethaphan Small molecule 6 mg Intravenous